Academic Bibliography

Search 200 years of publications by Ghent University researchers.

Sophie Vanherrewege

Ghent University Hospital

Add to list
- Journal Article
- A1
- open access
In-depth analysis of the HIV reservoir confirms effectiveness and safety of dolutegravir/lamivudine in a phase 4 randomized controlled switch trial (RUMBA)

Marie-Angélique De Scheerder (UGent) , Sophie Degroote (UGent) , Mareva Delporte (UGent) , Maja Kiselinova (UGent) , Wim Trypsteen (UGent) , Lara Vincke, Evelien De Smet (UGent) , Bram Van Den Eeckhout (UGent) , Loic Schrooyen (UGent) , Maxime Verschoore (UGent) , et al.

(2024) JOURNAL OF INFECTIOUS DISEASES. 231(1). p.e91-e100
Add to list
- Journal Article
- A1
- open access
Staging of immuno-virological dynamics during acute HIV infection in a Belgian prospective cohort study

Jozefien De Clercq (UGent) , Marie-Angélique De Scheerder (UGent) , Sophie Vanherrewege (UGent) , Els Caluwe (UGent) , Nathalie Moreels (UGent) , Danny Delooze, Annemieke Dhondt (UGent) , Marc Coppens (UGent) , Stefaan J. Vandecasteele, Sabine D. Allard, et al.

(2024) JOURNAL OF VIRUS ERADICATION. 10(3).
Add to list
- Conference Paper
- C3
Understanding changes in metabolic parameters switching to 2DR or 3DR integrase strand inhibitors (InSTIs)

Sophie Degroote (UGent) , Sophie Vanherrewege (UGent) , Els Tobback (UGent) , E. Caluwe, Lara Vincke, Evy Blomme (UGent) , Linos Vandekerckhove (UGent) and Marie-Angélique De Scheerder (UGent)

(2022) JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 25(Suppl. 6). p.138-139
Add to list
- Conference Paper
- C3
Impact of switch towards 3TC/dolutegravir on the intact and total viral reservoir in the Rumba study

Evy Blomme (UGent) , Wim Trypsteen (UGent) , Mareva Delporte (UGent) , C. Muccini, E. De Smet, Sophie Degroote (UGent) , Els Tobback (UGent) , Sophie Vanherrewege (UGent) , E. Caluwe, Marie-Angélique De Scheerder (UGent) , et al.

(2022) JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 25(Suppl. 6). p.13-14
Add to list
- Journal Article
- A1
- open access
Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting : a randomized placebo-controlled phase II trial

Els Tobback (UGent) , Sophie Degroote (UGent) , Sabine Buysse, Liesbeth Delesie (UGent) , Lucas Van Dooren, Sophie Vanherrewege (UGent) , Cyril Barbezange, Veronik Hutse, Marta Romano, Isabelle Thomas, et al.

(2022) INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 122. p.628-635